Your browser doesn't support javascript.
loading
Induction and exacerbation of subacute cutaneous lupus erythematosus following mRNA-based or adenoviral vector-based SARS-CoV-2 vaccination.
Kreuter, A; Licciardi-Fernandez, M J; Burmann, S-N; Burkert, B; Oellig, F; Michalowitz, A-L.
Afiliação
  • Kreuter A; Department of Dermatology, Venereology and Allergology, HELIOS St Elisabeth Hospital Oberhausen, University Witten/Herdecke, Witten, Germany.
  • Licciardi-Fernandez MJ; Department of Dermatology, Venereology and Allergology, HELIOS St Elisabeth Hospital Oberhausen, University Witten/Herdecke, Witten, Germany.
  • Burmann SN; Department of Dermatology, Venereology and Allergology, HELIOS St Elisabeth Hospital Oberhausen, University Witten/Herdecke, Witten, Germany.
  • Burkert B; Department of Dermatology, Venereology and Allergology, HELIOS St Elisabeth Hospital Oberhausen, University Witten/Herdecke, Witten, Germany.
  • Oellig F; Institute of Pathology, Mülheim an der Ruhr, Germany.
  • Michalowitz AL; Department of Dermatology, Venereology and Allergology, HELIOS St Elisabeth Hospital Oberhausen, University Witten/Herdecke, Witten, Germany.
Clin Exp Dermatol ; 47(1): 161-163, 2022 Jan.
Article em En | MEDLINE | ID: mdl-34291477
Evidence is accumulating that COVID-19 vaccines might induce or exacerbate autoimmune rheumatic diseases. The currently available COVID-19 vaccines include mRNA and recombinant adenoviral vector vaccines, both encoding SARS-CoV-2 spike protein production as the primary target for neutralizing antibodies. We report a case of subacute cutaneous lupus erythematosus (SCLE) following mRNA vaccination with the Pfizer mRNA vaccine BNT162b2, and summarize the current literature on CLE occurring after COVID-19 vaccination.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Lúpus Eritematoso Cutâneo / Toxidermias / COVID-19 / Vacina BNT162 Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Lúpus Eritematoso Cutâneo / Toxidermias / COVID-19 / Vacina BNT162 Idioma: En Ano de publicação: 2022 Tipo de documento: Article